ArticleAnnals of medicine and surgery (2012)2025
Machine learning and neuromyelitis optica: pioneering precision in disease diagnosiss.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in central nervous system autoimmune diseases: from clinical decision support to mechanistic discovery and translation.EMBO molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorder (sNMOSD) poses significant diagnostic challenges due to its clinical and radiologic similarities with multiple sclerosis (MS), despite requiring distinct therapeutic approaches. Early, accurate differentiation is essential to prevent irreversible disability and avoid inappropriate treatment. Machine learning (ML) offers a powerful means to detect subtle imaging differences, such as peri-ependymal lesions and area postrema involvement, often missed in conventional assessment. Recent advances include radiomics-based logistic regression models achieving AUCs above 0.92, compressed 3D convolutional neural networks outperforming traditional models, and transformer-based fusion networks integrating brain and spinal cord MRI with AUCs exceeding 0.93 for NMOSD classification. Incorporating immunological testing, particularly aquaporin-4 (AQP4) antibody status, further improves discrimination between NMOSD, MS, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). While promising, generalizability is limited by the scarcity of large, multi-center, diverse datasets. Combining advanced ML techniques with robust immunologic profiling offers a path toward precision diagnostics, enabling earlier intervention and improved outcomes for patients with NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.